Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation:: A randomized trial in a high-risk population

被引:73
作者
Plummer, Martyn
Vivas, Jorge
Lopez, Gladys
Bravo, Juan Carlos
Peraza, Simon
Carillo, Elsa
Cano, Elsa
Castro, Denis
Andrade, Olga
Sanchez, Victor
Garcia, Rita
Buiatti, Eva
Aebischer, Claude
Franceschi, Silvia
Oliver, Walter
Munoz, Nubia
机构
[1] Int Agcy Res Canc, F-69372 Lyon 08, France
[2] Ctr Control Canc Gastrointestinal Dr Luis Anderso, San Cristobal, Tachira State, Venezuela
[3] Univ Valle, Fdn Valle Lili, Dept Pathol, Cali, Colombia
[4] Reg Hlth Agcy Tuscany, Epidemiol Unit, Florence, Italy
[5] Hoffmann La Roche AG, Vitamins Div, Basel, Switzerland
[6] Inst Nacl Cancerol, Bogota, Colombia
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2007年 / 99卷 / 02期
关键词
D O I
10.1093/jnci/djk017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Gastric cancer is one of the most common malignancies worldwide. Histopathologic studies have identified a sequence of changes in the gastric mucosa that mark the slow progression from normal tissue to carcinoma. Epidemiologic evidence suggests that a diet rich in fresh fruit and vegetables could be a protective factor against this disease. This effect may be mediated through antioxidant vitamins. Methods A randomized, double-blind chemoprevention trial was conducted among 1980 subjects in Tachira State, Venezuela (whose population is at high risk for gastric cancer), to determine the effect of dietary supplementation with vitamin C, vitamin E, and beta-carotene on the progression and regression of precancerous gastric lesions. Subjects were randomly assigned to receive either a combination of vitamin C (750 mg/day), vitamin E (600 mg/day), and beta-carotene (18 mg/day) or placebo for 3 years. Changes in the gastric mucosa were determined by histologic diagnosis based on five biopsies taken from prespecified areas of the stomach at baseline and annually for 3 years. All biopsies were reviewed by a single expert pathologist. Progression rates (and regression rates) were calculated by comparing the first and last available gastroscopies for each subject and dividing the number of subjects whose diagnoses increased (decreased) in severity by the total follow-up time. Overall rate ratios were calculated by Poisson regression, controlling for baseline diagnosis. All statistical tests were two-sided. Results Median plasma vitamin levels were increased in the treatment group between baseline and 1 year after randomization from 0.43 mu mol/L (interquartile range [IQR] = 0.26-0.69) to 2.89 mu mol/L (IQR = 1.76-4.22) for beta-carotene, from 26.7 mu mol/L (IQR = 23.1-31.2) to 54.9 mu mol/L (IQR = 42.8-67.6) for alpha-tocopherol, and from 47.70 mu mol/L (IQR = 36.9-58.5) to 61.9 mu mol/L (IQR = 52.2-72.7) for vitamin C. Overall progression rates per 100 person-years were 74.3 in the placebo group and 67.8 in the group randomly assigned to vitamins. Overall regression rates were 109.4 in the placebo group and 116.5 in the group randomly assigned to vitamins. There was no statistically significant difference in progression rate (rate ratio = 0.92, 95% confidence interval [Cl] = 0.74 to 1.15) or regression rate (rate ratio = 1.09, 95% Cl = 0.90 to 1.33) between vitamin and placebo groups. Conclusion Supplementation with antioxidant micronutrients is not an effective tool for gastric cancer control in this high-risk population. The results of this trial are consistent with previous findings on the lack of effect of nutritional supplementation on precancerous gastric lesions.
引用
收藏
页码:137 / 146
页数:10
相关论文
共 41 条
[1]  
ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
[2]  
Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
[3]  
[Anonymous], MON EV CARC RISKS HU
[4]   NUTRITION INTERVENTION TRIALS IN LINXIAN, CHINA - SUPPLEMENTATION WITH SPECIFIC VITAMIN MINERAL COMBINATIONS, CANCER INCIDENCE, AND DISEASE-SPECIFIC MORTALITY IN THE GENERAL-POPULATION [J].
BLOT, WJ ;
LI, JY ;
TAYLOR, PR ;
GUO, WD ;
DAWSEY, S ;
WANG, GQ ;
YANG, CS ;
ZHENG, SF ;
GAIL, M ;
LI, GY ;
YU, Y ;
LIU, BQ ;
TANGREA, J ;
SUN, YH ;
LIU, FS ;
FRAUMENI, JF ;
ZHANG, YH ;
LI, B .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (18) :1483-1492
[5]   Stopping the active intervention: CARET [J].
Bowen, DJ ;
Thornquist, M ;
Anderson, K ;
Barnett, M ;
Powell, C ;
Goodman, G ;
Omenn, G .
CONTROLLED CLINICAL TRIALS, 2003, 24 (01) :39-50
[6]  
BRUBACHER G, 1974, CLIN BIOCH PRINCIPLE, V2, P989
[7]   DIFFICULTY IN ERADICATING HELICOBACTER-PYLORI IN A POPULATION AT HIGH-RISK FOR STOMACH-CANCER IN VENEZUELA [J].
BUIATTI, E ;
MUNOZ, N ;
VIVAS, J ;
CANO, E ;
PERAZA, S ;
CARILLO, E ;
CASTRO, D ;
SANCHEZ, V ;
ANDRADE, O ;
BENZ, M ;
DESANJOSE, S ;
OLIVER, W .
CANCER CAUSES & CONTROL, 1994, 5 (03) :249-254
[8]  
Buiatti E, 1996, INT J CANCER, V65, P317, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt
[9]  
317::AID-IJC7&gt
[10]  
3.0.CO